Amgen Inc ((AMGN)), BeOne Medicines ((ONC)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc., in collaboration with BeiGene, is conducting a Phase 1/2 clinical study titled ‘A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL.’ The study aims to evaluate the safety, efficacy, and pharmacokinetics of subcutaneous blinatumomab in treating R/R B-ALL and MRD+ B-ALL, which are challenging forms of leukemia.
The study is testing blinatumomab, a drug administered via subcutaneous injection, to determine its maximum tolerated dose and recommended phase 2 dose. The goal is to improve treatment outcomes for patients with these specific leukemia conditions.
The study design is interventional, non-randomized, and sequential, focusing on treatment as the primary purpose. There is no masking involved, meaning all participants and researchers are aware of the treatment being administered.
The study began on August 18, 2020, and is currently recruiting participants. The primary completion and estimated study completion dates are not specified, but the last update was submitted on August 20, 2025, indicating ongoing progress.
This study update could positively impact Amgen’s stock performance and investor sentiment, as successful results may enhance the company’s oncology portfolio. The collaboration with BeiGene also highlights strategic partnerships in the competitive pharmaceutical industry.
The study is ongoing, with further details available on the ClinicalTrials portal.